terrexine intramammary suspension
univet limited - cefalexin, kanamycin sulfate - intramammary suspension - unknown - antibacterials for intramammary use - bovine - antibacterial
ubrolexin intramammary suspension for lactating dairy cows
boehringer ingelheim ltd - cefalexin monohydrate, kanamycin sulfate - intramammary suspension - 20/13.3 mg/g - cefalexin, combinations with other antibacterials - bovine - antibacterial
ubrolexin intramammary suspension for lactating dairy cows
boehringer ingelheim limited - cefalexin, kanamycin - intramammary suspension - antimicrobial intramammary - cattle
kanacef m.c. intramammary suspension
interchem ireland ltd - cefalexin monohydrate; kanamycin monosulfate - intramammary suspension - . - cefalexin, combinations with other antibacterials - cattle - antibacterial
terrexine lc intramammary suspension for lactating cows
univet limited - cefalexin monohydrate; kanamycin monosulphate - intramammary suspension - . - antibacterials for intramammary use - cattle - antibacterial
ubrolexin intramammary suspension for lactating dairy cows
boehringer ingelheim ltd - cefalexin, kanamycin - intramammary suspension - 200 mg/100,000 iu per syringe - cefalexin, combinations with other antibacterials - cattle - antibacterial
ubrolexin intramammary suspension for lactating dairy cows
boehringer ingelheim animal health uk ltd - cefalexin, kanamycin - intramammary suspension - antimicrobial intramammary - cattle
ubrolexin intramammary suspension for lactating dairy cows
boehringer ingelheim animal health uk ltd - cefalexin, kanamycin - intramammary suspension - antimicrobial intramammary - cattle
ubrolexin intramammary suspension for lactating dairy cows
boehringer ingelheim animal health uk ltd - cefalexin, kanamycin - intramammary suspension - antimicrobial intramammary - cattle
shanghai microport medical firehawk liberty™ rapamycin target eluting coronary stent system
microport pte ltd - cardiovascular - the firehawk liberty™ rapamycin target eluting coronary stent system (firehawk liberty™ rtecss) is indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions length ≤ 60 mm with reference vessel diameters of ≥ 2.25 to ≤ 4.0 mm.